PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
Interleukin 6 (IL-6) is one of the key cytokines that are involved in inflammation and that has pleiotropic properties. Diverse effects of IL-6 result from the transmission of an intracellular signal in two ways: via direct binding to a membrane receptor having a molecular mass of 80 kDA (a classica...
Saved in:
| Main Author: | L. P. Ananyeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-02-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2155 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NEW CLASSIFICATION CRITERIA FOR SCLERODERMA SYSTEMATICA (a lecture)
by: Lidia Petrovna Ananyeva
Published: (2013-12-01) -
Diagnosis and treatment of interstitial lung disease in scleroderma systematica
by: L. P. Ananyeva
Published: (2018-06-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01) -
COMPLEX THERAPY FOR VASCULAR DISORDERS IN PATIENTS WITH SCLERODERMA SYSTEMATICA
by: M N Starovoitova, et al.
Published: (2009-06-01)